Search AI Products and News

According to Science and Technology Daily, the world's first generative artificial intelligence radiology system integrated into clinical processes developed by Northwestern University School of Medicine is revolutionizing medical imaging diagnostics. This system can identify life-threatening conditions within milliseconds, providing an innovative solution to the global shortage of radiologists. The AI system has been fully deployed in 12 hospitals affiliated with Northwestern University. In five months of actual application in 2024, the system successfully analyzed nearly 24,000 radiology reports, increasing report generation efficiency by an average of 15.5%, boosting work efficiency for some doctors.

Recently, Stanford University released a comprehensive evaluation of clinical medical AI models. DeepSeek R1 stood out as the champion among nine leading large models, achieving a 66% win rate and a macro average score of 0.75. The highlight of this evaluation is that it not only focuses on traditional medical license exam questions but also delves into the daily work scenarios of clinical doctors, providing more practical assessments. The evaluation team developed an integrated assessment framework called MedHELM, which includes 35 benchmarks covering 22 subtasks in medicine.

Amidst the rapid advancement of Artificial Intelligence (AI), Microsoft is actively promoting AI literacy with its 50-day AI Skills Festival. This event is open to everyone, from beginners to professionals, offering free registration and access to a wealth of AI learning resources. The initiative aims not only to enhance public AI capabilities but also to break a Guinness World Record, making it a fun and practical event. AI is transforming the way various industries operate, particularly in daily office work. Microsoft hopes to...

Baichuan Intelligent announced today that its 'AI Pediatrician', developed in collaboration with Beijing Children's Hospital and Pediatric Health Technology (Beijing) Co., Ltd., has officially entered clinical application after nearly a month of internal testing and expert approval. This milestone development marks an important step in the in-depth application of AI technology in the medical field. Image Source Note: Image generated by AI, authorized by Midjourney, was first launched yesterday by the National Children's Medical Center at Capital Medical University affiliated Beijing Children's Hospital featuring 'AI Pediatrician + Multidisciplinary'.

The next-generation AI application building platform 'Kouzi' has officially announced support for DeepSeek's R1 and V3 models, offering free trials to all users. It is reported that the Kouzi platform aims to assist users in rapidly building various bots based on large models and publishing them to social platforms, messaging apps, or websites.

Recently, Tencent Cloud TI Platform officially launched the highly anticipated DeepSeek series models, including the full version V3 with 671B parameters and the R1 original model, as well as a series of models distilled from DeepSeek-R1, with parameter sizes ranging from 70B to 1.5B. This initiative provides developers with powerful AI tool support and further promotes the popularization and application of large model technology.

At the recent World Economic Forum in Davos, Google DeepMind's CEO Demis Hassabis stated that the first drugs designed with the help of artificial intelligence could begin clinical trials by 2025. Hassabis also heads Isomorphic Labs, a drug research company under DeepMind. He stated, "Our plan is to have some AI-designed drugs enter clinical trials by the end of this year."

Recently, Demis Hassabis, one of the founders of Google, revealed in an interview that his company Isomorphic Labs plans to begin a clinical trial for a drug developed using artificial intelligence (AI) by the end of the year. This news has drawn significant attention, particularly regarding its potential applications in oncology, cardiovascular diseases, and neurodegenerative disorders. Image credit: Image generated by AI, image licensed from Midjourney Isomorphic.

Recently, pioneering company in the field of clinical AI, Aidoc, announced that it is collaborating with NVIDIA to develop a new guide called 'BRIDGE' (Blueprint for Resilient Integration and Deployment of Guided Excellence). The goal of this guide is to accelerate the adoption of artificial intelligence in the healthcare industry, with an expected release in early 2025.

Baidu Wenxin Yiyan is offering users a free 'Member Experience Card', allowing them to experience its latest large model 4.0 Turbo for up to 7 times. The offer is limited by time and instances, applicable to users who have received other experience cards. This model significantly enhances speed and effectiveness through technological innovation, integrating data, foundational models, alignment technology, and is jointly optimized with PaddlePaddle Wenxin, showcasing potential close to general artificial intelligence.

Abridge announced the completion of $150 million in Series C funding, garnering widespread attention after the launch of ChatGPT, which heightened interest in the clinical documentation field. The funding will impact Abridge's development and challenge competitors, bringing more intelligent solutions to the healthcare industry.

ChatGPT has an accuracy rate of 71.7% in clinical medical decision-making. It performs exceptionally well in primary care and emergency settings, demonstrating excellence in differential diagnosis, diagnostic testing, and clinical management tasks.

Researchers evaluated the racial and gender bias of GPT-4 in clinical decision-making and found significant biases. The study calls for bias assessments on large language models. The findings were published in The Lancet Digital Health.

🧪 Drug Discovery Process: The article mentions that it takes an average of 6 years for a drug to go from discovery to clinical trial phase. 📈 AI Companies Claim: AI startups claim that their drug candidate compounds have shortened the time from discovery to clinical trials to under 10 years, with some individual cases taking only 30 months. 🧐 Caution is Advised: These claims lack independent third-party verification, as clinical trials are necessary to test their feasibility.

Neuralink is recruiting patients with quadriplegia and ALS for its first human trial. The purpose of the trial is to assess the safety and functionality of the brain-computer interface implantation tool, marking a crucial step in Neuralink's advancement of clinical applications for brain-computer interfaces.